Alpha-toxin Provides Excellent Protection against NE; Other Proteins Likely Involved
Independent research by Canadian
investigators using state-of-the-art
technology confirms that alpha-toxin,
a secreted protein from Clostridium
perfringens, plays a key role in the
development of necrotic enteritis (NE)
in broilers and that other proteins may
also be involved in the pathogenesis
of this complex disease.
Immunization with alpha-toxin provided
almost total protection of broiler chickens
against NE, while other secreted proteins
produced by virulent C. perfringens
yielded various degrees of immunity,
Dr. John F. Prescott, of the University of
Guelph, Ontario, said at a meeting of the
Ontario Association of Poultry Practitioners
held in 2008 in Guelph.
Necrotic enteritis has become an
economically important disease for the
broiler industry. Although the cause is
known to be C. perfringens, exactly how this bacterium causes NE has been
uncertain, Prescott explained.
The major culprit has been assumed to be
alpha-toxin. Earlier this year, however,
Australian researchers published an article
about a novel C. perfringens toxin they
identified, called NetB. In widely publicized
findings, they indicated that NetB was the
main cause of NE and, on the basis of their
carefully conducted research, discounted
the role of alpha-toxin.
Canada study
Studies by Prescott and his colleagues,
however, show that immunization with
alpha-toxin provided the best protection
against a severe C. perfringens challenge
with a virulent strain that contains the
NetB gene.
In their studies, which Prescott reviewed
at the Ontario meeting, several proteins secreted by C. perfringens were evaluated
for their ability to protect broilers against
the virulent strain of the organism. The
proteins were alpha-toxin, glyceraldehyde-
3-phosphate dehydrogenase, pyruvate:
ferredoxin oxidoreductase (PFOR), fructose
1,6-biphosphate aldolase and a fifth one
called hypothetical protein (HP).
Broilers were immunized two to three
times with one of the proteins, then one
week after their last immunization, they
were challenged with the virulent strain,
which was administered in feed at
4 weeks of age.
The severity of the challenges differed;
a mild challenge, for instance, involved
feeding the virulent strain to birds three
times daily for 3 days, and the most
severe challenge involved feeding the
virulent strain daily to birds continuously
for 5 days. The severity of each challenge was confirmed by NE lesion
scores in non-immunized but challenged
control birds.
All the proteins significantly protected
broilers against the relatively mild
challenge. For the more severe
challenge, alpha-toxin, PFOR and HP
provided significant protection,
Prescott said.
Alpha-toxin provided best protection
The greatest protection against severe
challenge, however, occurred in birds that
were primed twice with alpha-toxoid —
a toxin that is altered so it is no longer
toxic but still initiates immunity — and then
boosted with active, purified toxin, Prescott
and colleagues found in their study,
published in 2007 in the September issue of
Clinical and Vaccine Immunology.
In addition, serum and intestinal washings
from protected birds had high antigenspecific
antibody titers for all proteins used
in their study, the researchers found.
This was the first report demonstrating
the immunizing ability of C. perfringens secreted
proteins in protecting broilers
against NE, Prescott and associates wrote.
They concluded that there are certain
secreted proteins, in addition to
alpha-toxin, involved in immunity to NE
in broiler chickens.
NetB
“I agree that
alpha-toxin should
be the main focus,”
but there may be
an advantage to
using more than
one protein."
NetB may be marker for NE strains
Prescott and associates also used polymerase
chain reaction to test the virulent
challenge strain and found it was positive
for the NetB gene.
“The fact...that immunization with
alpha-toxin strongly protected birds against
experimental NE caused by a
NetB-containing isolate suggests that
alpha-toxin actually is critical to the
development of NE, and perhaps that
NetB may only initiate infection,”
he said.
“I know that the Australian workers
think that the success of antibody against
alpha-toxin in protecting so well against
NE is because it may interfere with the
secretion of all proteins by this organism,
including, for example, the secretion of
NetB. It will be hard to prove this, and
actually may not matter if alpha-toxin
immunization works so well,” he added.
In addition, unpublished observations
from Ontario show that genetically
unrelated isolates from sick birds in
flocks with NE “were systematically
NetB-positive, whereas isolates from
healthy birds at slaughter were usually
negative” for NetB, he said.
“Almost but not quite all [C. perfringens]
isolates from birds with NE or from flocks
experiencing NE have NetB, so it’s a good
marker for a strain of C. perfringens that
causes necrotic enteritis,” Prescott said.
Asked by Intestinal Health why the search
continues for other secreted proteins when
it has already been shown that alpha-toxin
can protect broilers from NE, Prescott said,
“It will help us understand NE better, though I agree that alpha-toxin should be
the main focus. On the basis of the findings
of protection of birds following immunization,
alpha-toxin apparently has a central
role in NE,” but there may be an advantage
to using more than one protein.
Proteins differ, he added, in their structure,
in their activity, including toxicity, and in
their targets.
Favors vaccine
Methods for controlling NE might include
probiotics to provide bacterial competition
for C. perfringens or killing C. perfringens
with novel antibiotics, but Prescott favors
immunization.
“I think a vaccine probably has the most
promise because it should be the most
reliable. I like the idea of an oral vaccine
because it could also be used to deliver
other antigens and products,” said
Prescott, who has been experimenting
with an orally administered, attenuated
salmonella vaccine vector with
C. perfringens antigens.
Even though there is still much to be
learned about NE, he predicts rapid
advancement in the quest to conquer
the disease, thanks to large-scale genome
sequencing and other technologies. Due
to these advances, “scientists working
on NE around the world have made more
strides in the last 3 to 4 years than in the
previous 25 years,” he said.
Back to European Edition (#2)